Credelio Plus for Dogs 12.1-25 lbs (5.5-11 kg)

Description

Credelio Plus for Dogs 12.1-25 lbs (5.5-11 kg) delivers integrated flea, tick, heartworm, and intestinal worm control through a single monthly chewable tablet containing 225 mg lotilaner and 8.44 mg milbemycin oxime. This variant covers medium-small breed dogs that have outgrown the 6.1–12 lbs band, providing weight-calibrated dual-active dosing without requiring separate ectoparasiticide and endoparasiticide products.

Recommended for

Dogs weighing 12.1–25 lbs (5.5–11 kg) from 8 weeks of age.

Indication/Coverage

For dogs suffering from, or at risk from, mixed parasitic infections, the following indications apply to this variant:

• Flea treatment and prevention (Ctenocephalides felis, adults): lotilaner blocks GABA-gated chloride channels in the flea nervous system, producing kill within hours of the compound reaching systemic circulation.
• Flea allergy dermatitis prevention: consistent adult flea elimination curtails repeated cutaneous allergen deposition in sensitised dogs, reducing the frequency of allergic flare-ups.
• Tick treatment and prevention (Ixodes scapularis, Ixodes holocyclus, Rhipicephalus sanguineus, Amblyomma americanum, Dermacentor variabilis, adults): lotilaner reaches feeding ticks systemically following attachment, disrupting nervous system function before detachment occurs.
• Heartworm disease prevention (Dirofilaria immitis, L3/L4 larvae): milbemycin oxime eliminates infective larvae deposited during the preceding 30-day interval, maintaining prophylactic coverage when administered on schedule.
• Roundworm treatment (Toxocara canis, immature adults and adults): milbemycin oxime disrupts neuromuscular transmission in Toxocara canis across immature and mature life stages at the labeled monthly dose.
• Hookworm treatment (Ancylostoma caninum, immature adults and adults): active against both developmental stages of Ancylostoma caninum at the dose calibrated for this weight band.
• Whipworm treatment (Trichuris vulpis, adults): milbemycin oxime eliminates adult Trichuris vulpis as part of the standard monthly dosing cycle.

Key Benefits

The following reflects labeled performance data for Credelio Plus for Dogs 12.1–25 lbs:

• Weight-appropriate entry point: Labeled from 12.1 lbs (5.5 kg) at 8 weeks of age, this tablet is suited to medium-small breed puppies and adults transitioning from the lower weight band.
• Single-tablet parasite control: One monthly dose addresses fleas, five tick species, heartworm larvae, and three intestinal nematode genera, removing the clinical need for concurrent antiparasitic products.
• Systemic ectoparasiticide action: Lotilaner acts through systemic absorption following ingestion, reaching ectoparasites via the bloodstream rather than depending on topical residue distribution across the coat.
• Rapid flea kill: Greater than 98% flea kill is achieved within 12 hours of administration in fed dogs, reducing allergen load and flea burden before the next exposure cycle is established.
• Continuous heartworm prophylaxis: Each dose eliminates Dirofilaria immitis L3 and L4 larvae acquired over the preceding month, maintaining an unbroken protective interval when dosed consistently.
• Multi-stage nematode efficacy: Milbemycin oxime acts against immature adults and adults of Toxocara canis and Ancylostoma caninum, and adults of Trichuris vulpis, covering the full clinically relevant spectrum of intestinal worm burden in this size class.
• Chewable tablet formulation: The flavored oral tablet is appropriate for dogs in this weight range that resist spot-on application or for coats where consistent topical placement is difficult to achieve.
• 30-day protection duration: A single tablet sustains full parasite coverage for one calendar month across all labeled indications, provided the dosing interval does not exceed 30 days.

Caution

Hazards to Humans

Keep out of reach of children. Avoid ingestion and direct eye contact; if eye exposure occurs, flush immediately with running water. Wash hands thoroughly with soap and water after handling tablets or administering to the dog. Prevent contact between the product and food preparation surfaces or human food.

Hazards to Domestic Animals

Administer orally to dogs only; do not use in cats. This variant is indicated for dogs from 12.1 lbs (5.5 kg) at 8 weeks of age. Consult a veterinarian before administering to debilitated, aged, pregnant, or lactating animals. Lotilaner belongs to the isoxazoline class, which the FDA has associated with neurological adverse reactions including tremors, ataxia, and seizures in some dogs; prior veterinary clearance is required for dogs with a documented seizure or neurological history. Rare individual sensitivity reactions may occur. Exercise caution when co-administering with drugs that are P-glycoprotein substrates.

Possible Side Effects:

Monitor your dog after each administration of Credelio Plus, with particular attention following the first dose in animals with no prior exposure to isoxazoline or milbemycin oxime products.

Gastrointestinal reactions:

• Vomiting: The most commonly reported post-dose event; onset is typically within a few hours of administration and resolves without treatment in the majority of cases.
• Diarrhea: Observed in a proportion of clinical trial subjects; generally self-limiting and does not warrant treatment discontinuation in uncomplicated presentations.
• Inappetence: Transient reduction in appetite reported in some dogs during the first dosing cycle, resolving within 24 hours in most instances.

Systemic reactions:

• Lethargy: Temporary decrease in activity level following administration; typically resolves within one day without intervention.
• Pruritus: Skin irritation not attributable to active parasite burden; spontaneous resolution is the expected outcome in most cases.

Neurological reactions (isoxazoline class alert):

• Tremors, ataxia, or seizures: The FDA has issued a class-wide safety alert covering isoxazoline compounds, including lotilaner. These events are uncommon but documented; dogs with pre-existing neurological conditions are at elevated risk and require veterinary assessment before use.

Contact a veterinarian promptly if any adverse reaction persists or worsens, or if neurological signs emerge.